1-20 of 29
Han W. Tun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Carole Soussain, Samar Issa, Katharine L Lewis, Christian Grommes, Judith Fox, Renee Ward, Caryn Peterson, Matt Cravets, Anita Mathias, Judith Sosa, Brian J Kirby, Zhaoqing Ding, Isharat Yusuf, Mark J Rose, Marcos W Steinberg, Han W. Tun
Journal: Blood
Blood (2022) 140 (Supplement 1): 12068–12069.
https://doi.org/10.1182/blood-2022-158599
Published: 2022
Journal Articles

Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Primary Cutaneous CD30+ T-Cell Lymphoma: National Cancer Database Analysis (2004-2018)

Firas Baidoun, Jason Sluzevich, Han W. Tun, Mohamad Alhaj Moustafa
Journal: Blood
Blood (2022) 140 (Supplement 1): 9410.
https://doi.org/10.1182/blood-2022-165727
Published: 2022
Journal Articles

Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Lymphocyte-Depleted Hodgkin's Lymphoma: National Cancer Database Analysis (2004-2018)

Firas Baidoun, Bradford Hoppe, Han W. Tun, Mohamad Alhaj Moustafa
Journal: Blood
Blood (2022) 140 (Supplement 1): 9416–9417.
https://doi.org/10.1182/blood-2022-165686
Published: 2022
Journal Articles

Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience

Muhamad Alhaj Moustafa, Bijan J Borah, James P Moriarty, Ruchita Dholakia, Liuyan Jiang, Bradford Hoppe, Jennifer Peterson, James R. Cerhan, Han W. Tun
Journal: Blood
Blood (2021) 138 (Supplement 1): 4020.
https://doi.org/10.1182/blood-2021-153351
Published: 2021
Journal Articles

Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study

Yucai Wang, Betsy Laplant, Rebecca L. King, Ivana N. Micallef, Stephen M. Ansell, Han W. Tun, Madiha Iqbal, Gita Thanarajasingam, Allison C. Rosenthal, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 1415.
https://doi.org/10.1182/blood-2021-147507
Published: 2021
Journal Articles

Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant

Aung M Tun, Yucai Wang, Aasiya Matin, David J. Inwards, Patrick B. Johnston, Ivana N. Micallef, Luis F. Porrata, Jose C. Villasboas, Jonas Paludo, Han W. Tun, Allison C. Rosenthal, James R. Cerhan, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Stephen M. Ansell
Journal: Blood
Blood (2021) 138 (Supplement 1): 1373.
https://doi.org/10.1182/blood-2021-154038
Published: 2021
Journal Articles

Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience

Karan Seegobin, Muhamad Alhaj Moustafa, Umair Majeed, Liuyan Jiang, David Menke, Ke Li, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Madiha Iqbal, Grzegorz S. Nowakowski, Thomas M. Habermann, Thomas E. Witzig, Patrick B. Johnston, Carrie A. Thompson, Stephen M. Ansell, Han W. Tun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1452.
https://doi.org/10.1182/blood-2021-146408
Published: 2021
Journal Articles

CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM)

Ricardo Parrondo, MD, Muhamad Alhaj Moustafa, MD, Han W. Tun, MD, Liuyan Jiang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-139835
Published: 2020
Journal Articles

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Erel Joffe, MD MSc, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Monica Mead, MD BS, Daniel J. Landsburg, MD, Timothy S. Fenske, MD, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, MD MS, Alan Skarbnik, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD, Han W. Tun, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-140884
Published: 2020
Journal Articles

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Anas Younes, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Daniel J. Landsburg, MD, Elizabeth Martinez, PhD DHSC, MSN, Reinhard von Roemeling, MD, Christopher Lieberman, Han W. Tun, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-140857
Published: 2020
Journal Articles

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Anthony R. Mato, MD, Stephen J. Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Shalin K. Kothari, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Allison C. Rosenthal, D.O., Jose F. Leis, MD PhD, Han W. Tun, MD, Kaitlin Kennard, RN, BSN, Allison R. Nelson, RN, Victoria Falco, BSN, Celina J. Komari, BS, Amber B. Koehler, PA-C, MS, Rachel Stowe, RN, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Tim McKinlay, Lindsey E Roeker, MD, Meghan C. Thompson, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-138896
Published: 2020
Journal Articles

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Madiha Iqbal, MBBS, Yennifer Gil, Jonas Paludo, MD, Allison C. Rosenthal, D.O., Zhou Li, MS, Manuel Beltran, David J. Inwards, MD, Luis F. Porrata, MD, Ivana Micallef, MD, Jose C Villasboas, MD, Patrick B. Johnston, Stephen M. Ansell, MD PhD, Craig B. Reeder, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Han W. Tun, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Ernesto Ayala, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136332
Published: 2020
Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1591.
https://doi.org/10.1182/blood-2019-130449
Published: 2019
Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1544.
https://doi.org/10.1182/blood-2019-130384
Published: 2019
Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Anthony R. Mato, MDMSCE, Stephen J Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Han W. Tun, MD, Muhamad Alhaj Moustafa, MD, Kaitlin Kennard, RN, BSN, Cara M King, MPH, Amber Koehler, PA-C, MS, Casey Aitken, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Barry Douglas Anderson, MD PhD, Allison C. Rosenthal, DO, Lindsey E. Roeker, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 810.
https://doi.org/10.1182/blood-2019-126192
Published: 2019
Journal Articles

Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information

Anas Younes, MD, Grzegorz Nowakowski, MD, Allison C. Rosenthal, DO, Lori A. Leslie, MD, Han W. Tun, MD, Matthew A. Lunning, DO, FACP, Iris Isufi, MD, Robert Martell, MD PhD, Krish Patel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5327.
https://doi.org/10.1182/blood-2019-131851
Published: 2019
Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Megan Melody, MD, Sangeetha Gandhi, MBBS, Zaid Abdel Rahman, MD, Paula A Lengerke Diaz, MD, Nicole Gannon, PA-C, Allison C. Rosenthal, DO, Tuan Truong, Mattia Novo, Eva Brandes, Gina Lange, Breanna Estby, RN, Patrick Johnston, MD PhD, Stephen M Ansell, MD PhD, N. Nora Bennani, MD, Jonas Paludo, MD, Jose Villasboas, MD, Ernesto Ayala, MD, Han W. Tun, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Januario E. Castro, MD, Yi Lin, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5343.
https://doi.org/10.1182/blood-2019-126594
Published: 2019
Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5610.
https://doi.org/10.1182/blood-2019-122067
Published: 2019
Journal Articles

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2809.
https://doi.org/10.1182/blood-2019-129391
Published: 2019
Journal Articles

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma

Clinical Trials & Observations
Han W. Tun, Patrick B. Johnston, Lisa M. DeAngelis, Pamela J. Atherton, Levi D. Pederson, Patricia A. Koenig, Craig B. Reeder, Antonio M. Padula Omuro, David Schiff, Brian O’Neill, Jose Pulido, Kurt A. Jaeckle, Christian Grommes, Thomas E. Witzig
Journal: Blood
Blood (2018) 132 (21): 2240–2248.
https://doi.org/10.1182/blood-2018-02-835496
Published: 2018
Includes: Supplemental data